A Phase I Study of a Combination of 5-azacitidine Followed by Lenalidomide in High-risk MDS or Relapsed/Refractory AML Patients With Cytogenetic Abnormalities Including -5 or Del(5q).

Trial Profile

A Phase I Study of a Combination of 5-azacitidine Followed by Lenalidomide in High-risk MDS or Relapsed/Refractory AML Patients With Cytogenetic Abnormalities Including -5 or Del(5q).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 17 Dec 2013

At a glance

  • Drugs Azacitidine (Primary) ; Lenalidomide (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Acronyms AZALE
  • Most Recent Events

    • 01 Jul 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 24 Jun 2011 Planned end date changed from Dec 2012 to Jul 2013 as reported by ClinicalTrials.gov.
    • 24 Jun 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top